Cover Image
市場調查報告書

非小細胞肺癌 (NSCLC) :動態市場預測

Non-Small Cell Lung Cancer (NSCLC) - Dynamic Market Forecast to 2025

出版商 GlobalData 商品編碼 611765
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
非小細胞肺癌 (NSCLC) :動態市場預測 Non-Small Cell Lung Cancer (NSCLC) - Dynamic Market Forecast to 2025
出版日期: 2017年08月31日 內容資訊: 英文 65 Pages
簡介

本報告提供非小細胞肺癌 (NSCLC) 治療藥市場相關調查分析,最新的預測 (法規,上市,臨床實驗活動等) 相關的系統性資訊。

第1章 動態市場預測概要

  • 相關調查
  • 未來的相關調查

第2章 摘要整理

第3章 活動1

  • 主要的更新
  • Merck & Co.:Keytruda (pembrolizumab)
  • AstraZeneca:Imfinzi (durvalumab) + tremelimumab
  • Pfizer和Merck KGaA:Bavencio (avelumab)
  • Roche: Tecentriq (atezolizumab)
  • Novartis:Tafinlar (dabrafenib) + Mekinist (trametinib)
  • 其他
  • 摘要/趨勢
  • 資訊來源

第4章 活動2

  • 主要的更新
  • AstraZeneca:Tagrisso (osimertinib)
  • Pfizer:dacomitinib
  • 其他
  • 摘要/趨勢
  • 資訊來源

第5章 活動3

  • 主要的更新
  • Roche:Alecensa (alectinib)
  • 武田藥品工業:Alunbrig (brigatinib)
  • Pfizer:lorlatinib
  • 摘要/趨勢
  • 資訊來源

第6章 其他活動

  • 各種開發人員
  • 資訊來源

第7章 動態市場預測亮點

第8章 活動日曆

第9章 附錄

目錄
Product Code: GDHC001FS

The NSCLC therapeutics market is a rapidly evolving field in which new developments are constantly influencing the landscape. The Forecast Update is designed to help clients stay abreast of the latest news in the NSCLC space, including regulatory, commercial, and clinical events, and to understand how these events will impact the market forecast.

Scope

Key events covered in the Dynamic Market Forecast include -

  • Regulatory filings
  • Approval decisions
  • Pricing changes
  • Patent litigation
  • Clinical trial data announcements
  • Clinical trial failures
  • Clinical trial timeline updates

Components of the slide deck include -

  • Timeline of market-impacting events
  • Key clinical trial landscape updates
  • Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective
  • Overview of updates to the forecast model based on anticipated future impact of events
  • Forward-looking events calendar listing expected key updates to the NSCLC competitive space in the next quarter

Reasons to buy

  • Recent regulatory events
  • Recent commercial events
  • Recent clinical events
  • Market dynamics in the frontline NSCLC setting
  • Landscape changes in the EGFR-mutant NSCLC setting
  • Projected treatment algorithm shifts in the ALK-mutant NSCLC setting

Table of Contents

  • 1. Dynamic Market Forecast Overview 5
  • 1.1 Related Reports 6
  • 1.2 Upcoming Related Reports 7
  • 2. Executive Summary 8
  • 2.1 Key Events in Update 9-10
  • 2.2 Updates to Treatment Algorithms 11
  • 2.3 Clinical Trial Landscape Updates 12-13
  • 2.4 Pipeline Landscape Updates 14
  • 2.5 Market Insight on Key Events 15
  • 3. Event 1: Market Dynamics Shift in Frontline NSCLC 16
  • 3.1 Key Updates to the Frontline Non-squamous Setting 17
  • 3.2 Merck & Co., Keytruda (pembrolizumab) 18-19
  • 3.3 AstraZeneca, Imfinzi (durvalumab) + tremelimumab 20-21
  • 3.4 Pfizer and Merck KGaA , Bavencio (avelumab) 22
  • 3.5 Roche, Tecentriq (atezolizumab) 23
  • 3.6 Novartis, Tafinlar (dabrafenib) + Mekinist (trametinib) 24
  • 3.7 Additional Clinical Trial Updates- Frontline Setting 25-26
  • 3.8 Summary/Trends 27
  • 3.9 Sources 28
  • 4. Event 2: Weak Competition in the EGFRm+ Segment Creates Opportunity for Tagrisso 29
  • 4.1 Key Updates to the EGFRm+ Segment 30
  • 4.2 AstraZeneca, Tagrisso (osimertinib) 31-33
  • 4.3 Pfizer, dacomitinib 34
  • 4.4 Additional Clinical Trial Updates- EGFRm+ Setting 35
  • 4.5 Summary/Trends 36
  • 4.6 Sources 37
  • 5. Event 3: New SOC Anticipated in the ALKm+ 1L Setting 38
  • 5.1 Key Updates to the ALKm+ Setting 39
  • 5.2 Roche, Alecensa (alectinib) 40
  • 5.3 Takeda, Alunbrig (brigatinib) 41
  • 5.4 Pfizer, lorlatinib 42
  • 5.5 Summary/Trends 43
  • 5.6 Sources 44
  • 6. Other Events of Interest 45
  • 6.1 Various Developers 46-47
  • 6.2 Sources 48
  • 7. Dynamic Market Forecast Highlights 49
  • 7.1 Updates to Frontline NSCLC Segment 50
  • 7.2 Updates to EGFRm+ NSCLC Segment 51
  • 7.3 Updates to ALKm+ NSCLC Segment 52
  • 7.4 Selected Additional Forecast Updates 53
  • 8. Events Calendar 54
  • 8.1 Key Clinical Events Expected in Q4 2017 55-56
  • 9. Appendix 57
  • 9.1 Methodology 58
  • 9.2 Primary Research 59-60
  • 9.3 About the Authors 61-62
  • 9.4 About GlobalData 63
  • 9.5 Contact Us 64
  • 9.6 Disclaimer 65
Back to Top